Zentalis Pharmaceuticals, Inc.
ZNTLHealthcare|Biotechnology|US
$1.72
+0.01 (+0.58%)
Tangible Book / Share
$2.04
Cash / Share
$2.49
About
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Stock Price
+32.3%(1Y)
1M
-31.5%
3M
-59.2%
6M
-61.0%
YTD
+27.4%
1Y
+30.3%
3Y
-82.8%
5Y
-97.8%
Pipeline Summary
16 total trials11
Phase 1
7
Phase 2
1
Phase 3
0
Phase 4
Recruiting: 4Completed: 7Terminated: 4Withdrawn: 1
Active Trials (4)
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
NCT04516447Solid Tumor
Phase 1Recruiting
Enrollment: 172 participants
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
NCT07546500Ovarian Cancer
Phase 3Recruiting
Enrollment: 420 participants
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT05128825High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase 2Recruiting
Enrollment: 310 participants
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
NCT06369155Uterine Serous Carcinoma
Phase 2Recruiting
Enrollment: 25 participants
Key Facts
Market Cap$122.4M
Employees106 (-36% YoY)
CEOJulia Marie Eastland
IPO DateApr 3, 2020
Beta1.93
52-Week Range$1.25 – $6.95
Avg Volume1,212,977
ExchangeNASDAQ
Websitezentalis.com
Ownership
Float68.2%
Shares Outstanding71.2M
Recent Insider Trades
Bruns IngmarAWARD
Sep 30, 20269,727 shares @ $2.18
WALTERS GROUPBUY
Aug 14, 20264,335,000 shares @ $3.50
Johnson David MichaelAWARD
Jun 16, 202657,100 shares
Skvarka JanAWARD
Jun 16, 202657,100 shares
Walker Luke NathanielAWARD
Jun 16, 202657,100 shares
Peers
Recent News
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Nov 3, 2026 · globenewswire.com
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 2, 2026 · globenewswire.com
Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026
Oct 23, 2026 · globenewswire.com
HC Wainwright Reaffirms Buy Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL)
Oct 19, 2026 · defenseworld.net
Data last updated: Nov 9, 2026, 04:41 AM